Loading
Ionpath made the MIBIscope, an instrument that stains a thin slice of tumour for dozens of proteins at once with metal tags and reads them with an ion beam, so researchers can see which immune and cancer cells sit where. In 2025 the instrument business passed to Oregon Physics.
Ionpath, of Menlo Park, California, commercialised multiplexed ion beam imaging (MIBI), a technology originally developed at Stanford University in which antibodies tagged with metal isotopes are released from tissue by an ion beam and counted by mass spectrometry, measuring many proteins on one section. The MIBIscope was introduced commercially in 2019. In May 2022 Thermo Fisher Scientific made a strategic investment in the company on undisclosed terms. In 2025 Oregon Physics, which had built the instrument's primary ion source, acquired the MIBIscope platform's intellectual property and commercial rights and took over its manufacture, service and development; ionpath.com now redirects to the MIBIscope website run by Oregon Physics, which names oncology, immunology and tissue atlas studies among its applications.
Shares Spatial biology instruments, Single-cell & spatial profiling.
Shares Spatial biology instruments, Single-cell & spatial profiling.
Shares Imaging mass cytometry, Single-cell & spatial profiling.
Shares Spatial biology instruments, Single-cell & spatial profiling.
Shares Spatial biology instruments, Single-cell & spatial profiling.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/